Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
01 June 2004Website:
http://www.alnylam.comNext earnings report:
14 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Sat, 16 Nov 2024 00:59:53 GMTDividend
Analysts recommendations
Institutional Ownership
ALNY Latest News
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the presentation of new results from its Phase 1 study of nucresiran (formerly ALN-TTRsc04), a next-generation RNAi therapeutic in development for the treatment of transthyretin (ATTR) amyloidosis. The data were presented in an oral session at the American Heart Association Scientific Sessions 2024 in Chicago. These new results demonstrated that a single dose o.
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, with multiple FDA-approved treatments and a robust pipeline targeting rare and severe conditions. The company has strong growth potential, particularly with Amvuttra for ATTR-CM, which could become a major revenue driver in a growing market. Additionally, vutrisiran for ATTR-CM could capture a significant share of a projected $11.2 billion market.
Does Alnylam Pharmaceuticals (ALNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here is how Alnylam Pharmaceuticals (ALNY) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Alnylam's Amvuttra and Givlaari sales continue to boost revenues. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that two new data sets from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), were presented in the Late Breaking Clinical Research Session 1 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024, which was held virtually. An o.
Alnylam Pharmaceuticals NASDAQ: ALNY stock price action has been volatile but is uptrending and has gained 100% in the last two years. The uptrend is driven by increasing expectations for market-disrupting heart treatment and could double the price again.
Alnylam presents detailed data from the HELIOS-B study, seeking to expand Amvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy.
DALLAS--(BUSINESS WIRE)--Steward Health Care (“Steward”), the country's largest physician-led, minority-owned, integrated health care system, announced today it has reached an agreement in principle with its landlord, Medical Properties Trust, Inc. (“MPT”), supported by the “FILO” secured lenders under its funded debt and the official committee of unsecured creditors. Following Bankruptcy Court approval, the agreement allows for the transfer of hospitals that are governed by MPT's master lease.
What type of business is Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of RNA interference (RNAi) methods for treating genetically inherited diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. The company's lineup of RNAi therapeutic research focuses on four strategic therapeutic areas: genetic medicines, cardiovascular and metabolic diseases, infectious liver diseases, and CNS and eye diseases. The company has developed a unique gene deactivation-based treatment complex for inherited diseases that were previously incurable. Another 10 gene therapy products are in development.
What sector is Alnylam Pharmaceuticals in?
Alnylam Pharmaceuticals is in the Healthcare sector
What industry is Alnylam Pharmaceuticals in?
Alnylam Pharmaceuticals is in the Biotechnology industry
What country is Alnylam Pharmaceuticals from?
Alnylam Pharmaceuticals is headquartered in United States
When did Alnylam Pharmaceuticals go public?
Alnylam Pharmaceuticals initial public offering (IPO) was on 01 June 2004
What is Alnylam Pharmaceuticals website?
https://www.alnylam.com
Is Alnylam Pharmaceuticals in the S&P 500?
No, Alnylam Pharmaceuticals is not included in the S&P 500 index
Is Alnylam Pharmaceuticals in the NASDAQ 100?
No, Alnylam Pharmaceuticals is not included in the NASDAQ 100 index
Is Alnylam Pharmaceuticals in the Dow Jones?
No, Alnylam Pharmaceuticals is not included in the Dow Jones index
When was Alnylam Pharmaceuticals the previous earnings report?
No data
When does Alnylam Pharmaceuticals earnings report?
The next expected earnings date for Alnylam Pharmaceuticals is 14 February 2025